Aerovate Therapeutics Reports Q1 2025 Financials
Ticker: JBIO · Form: 10-Q · Filed: Apr 25, 2025 · CIK: 1798749
| Field | Detail |
|---|---|
| Company | Aerovate Therapeutics, INC. (JBIO) |
| Form Type | 10-Q |
| Filed Date | Apr 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
AVTE Q1 2025: $290M assets, $27.8M liabilities, $29M net loss. Cash burn continues.
AI Summary
Aerovate Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $289.85 million and total liabilities of $27.79 million as of March 31, 2025. For the three months ended March 31, 2025, the company had a net loss of $28.98 million.
Why It Matters
This filing provides a snapshot of Aerovate Therapeutics' financial health and operational performance for the first quarter of 2025, which is crucial for investors assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The company reported a significant net loss in the quarter, indicating ongoing cash burn and potential need for future financing.
Key Numbers
- $289.85M — Total Assets (As of March 31, 2025)
- $27.79M — Total Liabilities (As of March 31, 2025)
- $28.98M — Net Loss (For the three months ended March 31, 2025)
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- $289.85 million (dollar_amount) — Total assets as of March 31, 2025
- $27.79 million (dollar_amount) — Total liabilities as of March 31, 2025
- $28.98 million (dollar_amount) — Net loss for the three months ended March 31, 2025
FAQ
What was Aerovate Therapeutics' net loss for the first quarter of 2025?
Aerovate Therapeutics reported a net loss of $28.98 million for the three months ended March 31, 2025.
What were the total assets of Aerovate Therapeutics as of March 31, 2025?
As of March 31, 2025, Aerovate Therapeutics had total assets of $289.85 million.
What were the total liabilities of Aerovate Therapeutics as of March 31, 2025?
As of March 31, 2025, Aerovate Therapeutics had total liabilities of $27.79 million.
What is the fiscal year end for Aerovate Therapeutics?
Aerovate Therapeutics' fiscal year ends on December 31.
When was the 10-Q filing submitted?
The 10-Q filing was submitted on April 25, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 25, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).